DVA

—

Cap tier

—

Approx cap

—

Bull scenarios

Adverse scenarios

Bull scenarios (0)

Predictions where this ticker benefits

Pred	Role	Domain	Prediction	Predictor	Current	Move	Impact	Status
No data

Adverse scenarios (20)

Predictions where this ticker is displaced

Pred	Domain	Prediction	Predictor	Current	Move	Impact	Mechanism
245_011	Biotech/Longevity	Colossal is spinning out a dozen companies each with massive potential	Peter Diamandis	54.1%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_005	Biotech/Longevity	Countries will become customers to preserve endangered species via Colossal	Peter Diamandis	52.9%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
235_029	Biotech/Longevity	Big pharma companies will transition into longevity business in next 3 years.	Peter Diamandis	52.9%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
235_027	Biotech/Longevity	Longevity VC market expected to grow from $8.5B in 2024 to $12-18B in 2026.	Peter Diamandis	46.5%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_036	Biotech/Longevity	Colossal will continue seeding and spinning out new companies from scientific discoveries	Ben Lamm	45.0%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_041	Biotech/Longevity	Colossal will build a living lab in UAE in addition to Biovault	Ben Lamm	45.0%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_039	Biotech/Longevity	Colossal has not yet started work on dinosaurs, corals, dragons or Pokemon	Ben Lamm	45.0%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_007	Biotech/Longevity	Colossal will bring back the woolly mammoth	Ben Lamm	44.9%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_033	Biotech/Longevity	Colossal will work to reintroduce all de-extincted species back into their environments	Ben Lamm	44.3%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_014	Biotech/Longevity	Colossal has major announcements coming this year with a local government on productionizing cloning of endangered species	Ben Lamm	41.3%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_027	Biotech/Longevity	Colossal DNA synthesis delivery will reach 20x the largest prior delivery by end of 2026	Ben Lamm	41.0%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_006	Biotech/Longevity	Colossal will productionize species development via biobanking, synthetic biology, automation, AI, computer vision and artificial wombs	Ben Lamm	41.0%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_029	Biotech/Longevity	IVF will be transformed by Colossal's hydrogel/microfluidics embryo tech and new grading scale	Ben Lamm	40.6%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_026	Biotech/Longevity	Colossal editing tech will be applicable to human healthcare (spun out/licensed)	Ben Lamm	40.6%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_015	Biotech/Longevity	Colossal could theoretically create Pikachu (engineer novel designer organisms)	Ben Lamm	40.6%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
239_031	Biotech/Longevity	Ben Lamb / Colossal could engineer a Pikachu-like creature	Ben Lamm	40.6%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_045	Biotech/Longevity	Colossal considers Colossal platform core will stay focused on biodiversity and de-extinction	Ben Lamm	39.4%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
233_015	Biotech/Longevity	Infinite longevity is coming for this generation of kids.	Peter Diamandis	37.6%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_024	Biotech/Longevity	Colossal gene editing will reach thousands of edits (up from current hundreds)	Ben Lamm	34.2%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.
245_003	Markets/Stocks	Colossal's $10B valuation is massively undervalued	Ben Lamm	29.8%	unknown	unknown	Gene-editing cures shift from chronic recurring drug revenue to one-time therapies; chronic-drug franchises face long-tail erosion.